From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback